Citigroup Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) with Buy Recommendation

Fintel reported that on Dec. 9, 2025 Citigroup initiated coverage of Ligand Pharmaceuticals' Equity Right (OTCPK:LGNXZ) with a Buy recommendation; however, aggregated analyst data as of Dec. 6 shows an average one‑year price target of $0.00 (range $0–$0), which the report frames as a 23.5% downside from the latest reported closing price of $0.00. The profile includes a projected annual revenue of $161 million (down 35.8%) and projected non‑GAAP EPS of $3.99. Institutional ownership is small and unchanged quarter‑over‑quarter—five funds hold roughly 425K shares, dominated by Vanguard Extended Market Index Fund (396K)—indicating limited active investor engagement and potential valuation or liquidity complexity for this equity right.

Analysis

Fintel reports that Citigroup initiated coverage of Ligand Pharmaceuticals' Equity Right (OTCPK:LGNXZ) with a Buy on December 9, 2025, but the aggregated analyst data as of December 6 lists an average one‑year price target of $0.00 (range $0–$0) and a reported 23.50% implied downside versus the latest quoted closing price of $0.00, indicating either a data anomaly or an illiquid/complex instrument rather than a conventional equity valuation. The Fintel profile cites projected annual revenue of $161 million, a 35.8% decline, alongside a projected non‑GAAP EPS of $3.99, a combination that suggests materially lower top‑line expectations while reporting positive per‑share earnings metrics for the equity right as presented. Institutional positioning is minimal and stable: five funds hold ~425K shares with Vanguard Extended Market Index Fund owning 396K and no quarter‑over‑quarter change, implying passive/index concentration and limited active investor engagement. Sentiment outputs are moderately negative (overall −0.45, LGND −0.6), underscoring market skepticism; the primary risks are data/valuation opacity, instrument liquidity, and inconsistent analyst signals that must be resolved before sizing exposure.

Key Decisions for Investors

• Do not initiate a meaningful position until primary-source disclosures and Citigroup's report are reviewed to resolve the $0.00 price-target/closing-price anomaly and to understand the equity right's valuation mechanics
• Given a projected 35.8% revenue decline, a reported non-GAAP EPS of 3.99, and concentrated passive ownership, limit any exposure to a small, liquid-size position and avoid reliance on the Buy call alone
• Monitor follow-up analyst notes, institutional flow changes and trading liquidity closely and consider hedging or waiting for clearer market pricing before increasing exposure